ADVM Valuation
Adverum Biotechnologies Inc
$
2.300
- Overview
- Forecast
- Valuation
ADVM Relative Valuation
ADVM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ADVM is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for ADVM's competitors is 89.68, providing a benchmark for relative valuation. Adverum Biotechnologies Inc Corp (ADVM) exhibits a P/S ratio of 225.40, which is 151.35% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
People Also Watch
GOOG
Alphabet Inc
170.850
USD
+3.35%
NVDA
NVIDIA Corp
133.230
USD
-0.86%
GOOGL
Alphabet Inc
169.990
USD
+3.67%
AAPL
Apple Inc
202.960
USD
-1.89%
COYA
Coya Therapeutics Inc
5.860
USD
0.00%
MSFT
Microsoft Corp
454.010
USD
-0.91%
META
Meta Platforms Inc
636.050
USD
-0.16%
TSLA
Tesla Inc
338.590
USD
-1.52%
AMZN
Amazon.com Inc
201.549
USD
-1.24%
DTSQ
DT Cloud Star Acquisition Corp
10.360
USD
-0.78%
FAQ
Is Adverum Biotechnologies Inc (ADVM) currently overvalued or undervalued?
Adverum Biotechnologies Inc (ADVM) is now in the Fair zone, suggesting that its current forward PS ratio of 225.40 is considered Fairly compared with the five-year average of 709.20. The fair price of Adverum Biotechnologies Inc (ADVM) is between to according to relative valuation methord.
What is Adverum Biotechnologies Inc (ADVM) fair value?
How does ADVM's valuation metrics compare to the industry average?
What is the current P/B ratio for Adverum Biotechnologies Inc (ADVM) as of May 21 2025?
What is the current FCF Yield for Adverum Biotechnologies Inc (ADVM) as of May 21 2025?
What is the current Forward P/E ratio for Adverum Biotechnologies Inc (ADVM) as of May 21 2025?